Biodexa shares surge 15.94% premarket after securing exclusive license for Otsuka’s Phase 1-ready molecular glue for GIST.

Biodexa Pharmaceuticals Plc (BDRX) rose 15.94% in premarket trading following the announcement of an exclusive license for Otsuka’s OPB-171775, a Phase 1-ready molecular glue targeting gastrointestinal stromal tumors (GIST). The deal, disclosed 16 minutes prior, provides access to a preclinical asset with potential therapeutic applications, signaling progress in Biodexa’s drug development pipeline. This strategic partnership aligns with the company’s focus on oncology innovation and could enhance its competitive positioning in the biopharma sector. Other recent news, including a prior CFO appointment and a $10 million public offering, lacked immediate market impact compared to the licensing agreement, which directly addresses R&D advancements.